Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus rating of “Moderate Buy” from the twenty-three brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, twenty-one have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $121.4091.

A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 25th. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a report on Monday, June 8th. Finally, B. Riley Financial boosted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 77,109 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the transaction, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director directly owned 472,267 shares in the company, valued at $52,086,327.43. This trade represents a 49.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 3,663,505 shares of company stock worth $392,560,235. Corporate insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its position in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. GAMMA Investing LLC increased its position in Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Kymera Therapeutics during the 4th quarter worth about $63,000.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $114.16 on Thursday. The firm has a market capitalization of $9.39 billion, a P/E ratio of -31.98 and a beta of 1.95. Kymera Therapeutics has a one year low of $36.65 and a one year high of $130.05. The company’s fifty day moving average is $89.15 and its two-hundred day moving average is $83.82.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter last year, the firm posted ($0.82) EPS. The business’s revenue was up 55.5% compared to the same quarter last year. On average, sell-side analysts forecast that Kymera Therapeutics will post -3.28 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.